Brainstorm Cell Therapeutics Inc. – NASDAQ:BCLI
Brainstorm Cell Therapeutics stock price today
$0.65
-1.80
-73.47%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in 39 minutes
Brainstorm Cell Therapeutics stock price monthly change
+483.33%
month
Brainstorm Cell Therapeutics stock price quarterly change
+483.33%
quarter
Brainstorm Cell Therapeutics stock price yearly change
+756.64%
year
Brainstorm Cell Therapeutics key metrics
Market Cap | 12.43M |
Enterprise value | 104.60M |
P/E | -4.33 |
EV/Sales | N/A |
EV/EBITDA | -5.50 |
Price/Sales | N/A |
Price/Book | 75.19 |
PEG ratio | -0.04 |
EPS | -0.32 |
Revenue | N/A |
EBITDA | -23.49M |
Income | -15.53M |
Revenue Q/Q | N/A |
Revenue Y/Y | -139.77% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBrainstorm Cell Therapeutics stock price history
Brainstorm Cell Therapeutics stock forecast
Brainstorm Cell Therapeutics financial statements
| Jun 2023 | 154K | -5.32M | -3460.39% |
|---|---|---|---|
| Sep 2023 | 0 | -1.22M | |
| Dec 2023 | 343K | -5.57M | -1626.24% |
| Mar 2024 | -569K | -3.40M | 597.72% |
| 2025 | 258M | -24M | -9.3% |
|---|---|---|---|
| 2026 | 426.89M | -26.5M | -6.21% |
| 2027 | 445.78M | -3.44M | -0.77% |
| 2028 | 136.31M | 9.90M | 7.27% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 5747000 | 9.62M | 167.55% |
|---|---|---|---|
| Sep 2023 | 5682000 | 8.26M | 145.44% |
| Dec 2023 | 4208000 | 9.06M | 215.45% |
| Mar 2024 | 3348000 | 8.89M | 265.77% |
| Jun 2023 | -6.77M | 4K | 5.29M |
|---|---|---|---|
| Sep 2023 | -6.40M | -12K | 7.09M |
| Dec 2023 | -3.28M | 196K | 3.35M |
| Mar 2024 | -3.06M | 0 | 2.53M |
Brainstorm Cell Therapeutics alternative data
| Aug 2023 | 41 |
|---|---|
| Sep 2023 | 44 |
| Oct 2023 | 44 |
| Nov 2023 | 44 |
| Dec 2023 | 42 |
| Jan 2024 | 42 |
| Feb 2024 | 42 |
| Mar 2024 | 42 |
| Apr 2024 | 42 |
| May 2024 | 29 |
| Jun 2024 | 29 |
| Jul 2024 | 29 |
Brainstorm Cell Therapeutics other data
8.63%
-1.50%
of BCLI is owned by hedge funds
29
-13
3.15M
-544.39K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2023 | 11500 | 0 |
| Quarter | Transcript |
|---|---|
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 15 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 30 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Chaim Lebovits (1971) Chief Executive Officer | $1,640,000 |
| Dr. Ralph Z. Kern (1958) Pres & Chief Medical Officer | $844,220 |
BrainStorm: Upcoming AdCom Meeting For NurOwn For ALS Could Be Start Of Major Turnaround
Athersys: Is Big Pharma Sleeping At The Wheel?
Brainstorm Cell Therapeutics: Upcoming BLA In ALS
Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022
Brainstorm Cell Therapeutics: MSC-NTF Cell Therapy Shows Mid-Stage Promise In PMS
-
What's the price of Brainstorm Cell Therapeutics stock today?
One share of Brainstorm Cell Therapeutics stock can currently be purchased for approximately $0.65.
-
When is Brainstorm Cell Therapeutics's next earnings date?
Unfortunately, Brainstorm Cell Therapeutics's (BCLI) next earnings date is currently unknown.
-
Does Brainstorm Cell Therapeutics pay dividends?
No, Brainstorm Cell Therapeutics does not pay dividends.
-
How much money does Brainstorm Cell Therapeutics make?
Brainstorm Cell Therapeutics has a market capitalization of 12.43M.
-
What is Brainstorm Cell Therapeutics's stock symbol?
Brainstorm Cell Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "BCLI".
-
What is Brainstorm Cell Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Brainstorm Cell Therapeutics?
Shares of Brainstorm Cell Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Brainstorm Cell Therapeutics's key executives?
Brainstorm Cell Therapeutics's management team includes the following people:
- Mr. Chaim Lebovits Chief Executive Officer(age: 54, pay: $1,640,000)
- Dr. Ralph Z. Kern Pres & Chief Medical Officer(age: 67, pay: $844,220)
-
How many employees does Brainstorm Cell Therapeutics have?
As Jul 2024, Brainstorm Cell Therapeutics employs 29 workers, which is 31% less then previous quarter.
-
When Brainstorm Cell Therapeutics went public?
Brainstorm Cell Therapeutics Inc. is publicly traded company for more then 21 years since IPO on 7 Oct 2003.
-
What is Brainstorm Cell Therapeutics's official website?
The official website for Brainstorm Cell Therapeutics is brainstorm-cell.com.
-
Where are Brainstorm Cell Therapeutics's headquarters?
Brainstorm Cell Therapeutics is headquartered at 1325 Avenue of Americas, New York, NY.
-
How can i contact Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics's mailing address is 1325 Avenue of Americas, New York, NY and company can be reached via phone at +20 14880460.
Brainstorm Cell Therapeutics company profile:
Brainstorm Cell Therapeutics Inc.
brainstorm-cell.comExchange:
NASDAQ
Full time employees:
29
Industry:
Biotechnology
Sector:
Healthcare
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
1325 Avenue of Americas
New York, NY 10019
New York, NY 10019
CIK: 0001137883
ISIN: US10501E2019
CUSIP: 10501E201
